コンテンツへスキップ
Merck
  • Reversible posterior encephalopathy syndrome in systemic lupus erythematosus and lupus nephritis.

Reversible posterior encephalopathy syndrome in systemic lupus erythematosus and lupus nephritis.

Internal medicine (Tokyo, Japan) (2008-05-03)
Yan-Xing Zhang, Jian-Ren Liu, Mei-Ping Ding, Jian Huang, Min Zhang, Olav Jansen, Günther Deuschl, Christoph Cyrill Eschenfelder
要旨

Reversible posterior encephalopathy syndrome (RPES) is a clinical entity characterized with headache, nausea, vomiting, seizures, consciousness disturbance, and frequently visual disorders associated with neuroradiological findings, predominantly white matter abnormalities of the parieto-occipital lobes. The central nervous system manifestations of systemic lupus erythematosus (SLE) are highly diverse. However, SLE-associated RPES has been seldom reported. Here, we report a case with RPES in SLE and lupus nephritis with exclusive involvement of parietal and occipital cortices. A systematic review of the literature on the pathogenesis and treatment of SLE-associated RPES is included.

材料
製品番号
ブランド
製品内容

Cilazapril, European Pharmacopoeia (EP) Reference Standard
Cilazapril impurity D, European Pharmacopoeia (EP) Reference Standard